肌基质蛋白 | 267402-71-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 肌基质蛋白
• 中文别名: 9-异丙基-2,6-二(4-甲氧苯基氨基)嘌呤
• 英文名称: Myoseverin
• 英文别名: 2-N,6-N-bis[(4-methoxyphenyl)methyl]-9-propan-2-ylpurine-2,6-diamine
• CAS: 267402-71-1
• 化学式: C₂₄H₂₈N₆O₂
• 分子量: 432.5
• InChiKey: IDCOTQWQVPRTNK-UHFFFAOYSA-N

物化性质

• 熔点：
  106.0 to 110.0 °C
• 沸点：
  661.3±65.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  氯仿：可溶50 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  86.1
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

生物活性

Myoseverina，一种微管结合分子，诱导多核肌管可逆分裂为单核片段。Myoseverina 影响多种生长因子、免疫调节、细胞外基质重塑和应激反应基因的表达，与创伤愈合和组织再生相关通路的激活一致。

文献信息

• DRUG COMBINATIONS TO TREAT HYPERPROLIFERATIVE DISORDERS
  申请人：Maurer Barry James

  公开号：US20100035911A1

  公开（公告）日：2010-02-11

  A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of microtubule structure or function; or (b) a combination containing fenretinide (i.e., N-(4-hydrophenyl) retinamide, 4-HPR) and ABT-751 (i.e., N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide). Vitamin A derivatives that may be useful for this invention according to (a) include, but are not limited to, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide. Microtubule inhibitors that may be useful for this invention according to (a) include, but are not limited to, inhibitors of the Vinca binding domain (e.g., vincristine, vinblastine, vinorelbine, and cryptophycin 52), inhibitors of the Taxane domain (e.g., paclitaxel, docetaxel, and epothilones), and inhibitors of the colchicine site (e.g., colchicine, ABT-751, CI-980, and combretastatin). A preferred retinoid according to (a) is fenretinide. A preferred microtubule inhibitor according to (b) is ABT-751.
• COMPOSITIONS AND METHODS FOR CONTROLLING NATURAL KILLER CELL ACTIVATION AND FUNCTION
  申请人：BAR ILAN UNIVERSITY

  公开号：US20190343801A1

  公开（公告）日：2019-11-14

  The present invention provides means to affect the dynamics of actomyosin network in natural killer (NK) cells, and thereby to confer selective control on killing efficiencies of NK cell populations. Compositions and methods of the present invention, particularly those using small molecules, provide a powerful tool for controlling NK cell activation and function in various conditions, in health and disease, most notably in viral infections, autoimmunity, immunodeficiency, GVHD and cancer.
• US7718655B2
  申请人：——

  公开号：US7718655B2

  公开（公告）日：2010-05-18
• [EN] COMPOSITIONS AND METHODS FOR CONTROLLING NATURAL KILLER CELL ACTIVATION AND FUNCTION<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE RÉGULATION DE L'ACTIVATION ET DE LA FONCTION DE CELLULES TUEUSES NATURELLES
  申请人：UNIV BAR ILAN

  公开号：WO2018134817A1

  公开（公告）日：2018-07-26

  The present invention provides means to affect the dynamics of actomyosin network in natural killer (NK) cells, and thereby to confer selective control on killing efficiencies of NK cell populations. Compositions and methods of the present invention, particularly those using small molecules, provide a powerful tool for controlling NK cell activation and function in various conditions, in health and disease, most notably in viral infections, autoimmunity, immunodeficiency, GVHD and cancer.